Ключевые слова:
tizimli sklerodermiya, fibroz, immun holat, TGF-β, IL-6Библиографические ссылки
1. Allanore Y, Distler O, Matucci-Cerinic M. Systemic sclero- sis. Lancet.2021;398(10303):1687-703.
2. Buranova SN, Akhmedov KhS, Razakova FS. Cartilage oligomeric matrix protein (COMP) in early diagnosis of osteoar- thritis. Chin J Occup Dis Labor and Health.2021.39(7):93-100.
3. Buranova SN, Akhmedov KhS, Razakova FS. The Impor- tance of Treatment Aimed at the Dynamics of Cartilage Oligo- mer Matrix Protein (COMP) in Patients with the Knee Joint Os- teoarthritis. Amer J Med Med Sci.2021.11(2):148-53.
4. Cutolo M, Smith V. Detection of microvascular changes in systemic sclerosis and other rheumatic diseases. Nat Rev Rheumatol.2021;17(11):665-77.
5. Denton CP, Khanna D. Systemic sclerosis. Lan- cet.2019;394(10197):1685-99.
6. Distler JHW, Highland KB, Gahlemann M et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. New Engl J Med.2019;380(26):2518-28.
7. Hoffmann-Vold AM, Allanore Y, Alves M et al. Progres- sive interstitial lung disease in patients with systemic scle- rosis-associated ILD in the EUSTAR database. Ann Rheum Dis.2021;80(2):219-27.
8. Huang J, Ma J, Chen H et al. Transforming growth fac- tor-beta signaling in systemic sclerosis pathogenesis and ther- apy. Front Immunol.2022;13:868359.
9. Jordan S, Distler JHW, Maurer B. Cytokine and growth factor signatures in systemic sclerosis. Front Immu- nol.2021;12:686381.
10. Khalmetova FI, Akhmedov XS, Alibekova GA. Features of
the course of the joint syndrome in various forms of reactive arthritis. Galaxy Int Interdisciplinary Res J.2023;11(4):832-7.
11. Khanna D, Tashkin DP, Denton CP et al. Tocilizumab in systemic sclerosis: A randomized, double-blind, placebo-con- trolled, phase 3 trial. Lancet Respir Med.2020;8(10):963-74.
12. Lafyatis R. Transforming growth factor β – at the centre of systemic sclerosis. Nat Rev Rheumatol. 2020;16(6):337-48.
13. Rakhimova MB. Impared endothelial dysfunction in covid-19: an overview of evidence, biomarkers in patients with ankylosing spondylitis. Int Multidisciplinary Res Acad Sci.2023;6(7):20-7.
14. Rakhimova M et al. Endothelin-1biomarker Features in Patients with Ankylosing Spondylitis after COVID-19. J Positive School Psychol.2022;6:6.
15. Shapira S, Agmon-Levin N, Shoenfeld Y. Fibrosis in auto- immune diseases: Pathogenesis and therapeutic targets. Nat Rev Rheumatol.2020;16(12):725-39.
